Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
35.45
-1.90 (-5.09%)
Mar 31, 2025, 9:43 AM EDT - Market open

Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

The company’s research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).

The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.

Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.
Revolution Medicines logo
Country United States
Founded 2014
IPO Date Feb 13, 2020
Industry Biotechnology
Sector Healthcare
Employees 534
CEO Mark Goldsmith

Contact Details

Address:
700 Saginaw Drive
Redwood City, California 94063
United States
Phone 650 481 6801
Website revmed.com

Stock Details

Ticker Symbol RVMD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001628171
CUSIP Number 76155X100
ISIN Number US76155X1000
Employer ID 47-2029180
SIC Code 2836

Key Executives

Name Position
Dr. Mark A. Goldsmith Ph.D. Chief Executive Officer, President and Chairman
Jack Anders Chief Financial Officer
Margaret A. Horn J.D. Chief Operating Officer
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. President of Research and Development
Xiaolin Wang Executive Vice President of Development
Dr. Martin D. Burke M.D., Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder and Member of Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder and Member of Scientific Advisory Board
Walter Reiher Ph.D. Chief Information Officer
Jan Smith Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 144 Filing
Mar 14, 2025 144 Filing
Mar 14, 2025 144 Filing
Mar 14, 2025 144 Filing
Mar 14, 2025 144 Filing
Mar 14, 2025 144 Filing
Feb 26, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 26, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing